Koerner Anna S, Zhou Maggie, Brook Ashley, Yoon Sam S, Ganjoo Kristen N
Surgical Oncology, Surgery, Columbia University Irving Medical Center, New York, USA.
Hematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
Cureus. 2023 Dec 22;15(12):e50967. doi: 10.7759/cureus.50967. eCollection 2023 Dec.
Sclerosing epithelioid fibrosarcoma (SEF) is an extremely rare subtype of sarcoma that appears histologically low-grade yet usually has a clinically aggressive course with a high rate of local recurrence and distant metastasis. However, these recurrences and metastases often occur years after initial treatment. Metastases can be to the lung as well as extra-pulmonary sites. In this case report, we discuss a patient who developed SEF in the deep soft tissue with metastases. This patient underwent checkpoint inhibitor therapy, with disease response. Thus, SEF is a sarcoma subtype with a unique tumor biology, and immunotherapy may be a promising avenue for treatment.
硬化性上皮样纤维肉瘤(SEF)是一种极其罕见的肉瘤亚型,其组织学表现为低级别,但临床过程通常具有侵袭性,局部复发率和远处转移率较高。然而,这些复发和转移往往在初始治疗数年之后才会出现。转移部位可以是肺部以及肺外部位。在本病例报告中,我们讨论了一名在深部软组织发生SEF并伴有转移的患者。该患者接受了检查点抑制剂治疗,并出现了疾病反应。因此,SEF是一种具有独特肿瘤生物学特性的肉瘤亚型,免疫疗法可能是一种有前景的治疗途径。